Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.87 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.87 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.87 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.87 |
| ▸ | TSHR | P16473 | 1/20 | 0.87 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.62 |
| ▸ | F7 | P08709 | 3/20 | 0.62 |
| ▸ | F3 | P13726 | 3/20 | 0.62 |
| ▸ | PPARG | P37231 | 3/20 | 0.62 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | PPARD | Q03181 | 2/20 | 0.62 |
| ▸ | PPARA | Q07869 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Icosapent Ethyl SCHEMBL119167 | 1.00 | ADORA3 (1.00) | ADORA3NR1I2PTGS2PGRPDE4D | |
| Icosapent Ethyl SCHEMBL28366934 | 1.00 | ADORA3 (1.00) | ADORA3NR1I2PTGS2PGRPDE4D | |
| Icosapent Ethyl SCHEMBL28253974 | 1.00 | ADORA3 (1.00) | ADORA3NR1I2PTGS2PGRPDE4D | |
| Icosapent Ethyl SCHEMBL123305 | 1.00 | ADORA3 (1.00) | ADORA3NR1I2PTGS2PGRPDE4D | |
| Icosapent Ethyl SCHEMBL29356075 | 0.97 | ADORA3 (0.93) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL28628574 | 0.95 | ALDH1A1 (0.97) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL21670446 | 0.95 | ALDH1A1 (0.97) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL21670445 | 0.95 | ALDH1A1 (0.97) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL18924751 | 0.94 | ADORA3 (0.89) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL4814473 | 0.93 | ALDH1A1 (1.00) | ADORA3NR1I2PTGS2PGRPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 433 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216322-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-07-04 | — | — | US | disclosed |
| US-20240148683-A1 | STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-05-09 | — | — | US | disclosed |
| US-20240024277-A1 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA | AMARIN PHARMA, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240016803-A1 | PHARMACEUTICAL COMPOSITION COMPRISING EICOSAPENTAENOIC ACID AND DERIVATIVES THEREOF AND A STATIN | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-01-18 | — | — | US | disclosed |
| US-20230310372-A1 | CO-ADMINISTRATION OF ATORVASTATIN AND ETHYL EICOSAPENTAENOIC ACID OR A DERIVATIVE THEREOF | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-10-05 | — | — | US | disclosed |
| US-20230248741-A1 | Compositions and Methods for Lowering Triglycerides in a Subject with Reduced Kidney Function and Diabetes Mellitus | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-08-10 | — | — | US | disclosed |
| US-11712428-B2 | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-08-01 | — | — | US | disclosed |
| US-11712429-B2 | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-08-01 | — | — | US | disclosed |
| US-20230210806-A1 | COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES | AMARIN PHARMA, INC. | 2023-07-06 | — | — | US | disclosed |
| US-11690820-B2 | Methods of treating mixed dyslipidemia | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-07-04 | — | — | US | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20060121583-A1 | New method for synthesizing ceramide-type compounds | LASSALLE LAURENT | 2006-06-08 | — | — | US | disclosed |
| EP-0782827-B1 | USE OF A BALANCING AGENT FOR OMEGA-6 AND OMEGA-3 UNSATURATED FATTY ACIDS | SUNTORY LTD (JP) | 2003-10-01 | — | — | EP | disclosed |
| US-20020095007-A1 | Lewis acid-catalyzed polymerization of biological oils and resulting polymeric materials | IOWA STATE UNIVERSITY RESEARCH FOUNDATION | 2002-07-18 | — | — | US | disclosed |
| US-6159507-A | Food composition containing an omega-6/omega-3 unsaturated fatty acid balance modifier | SUNTORY LIMITED (JP) | 2000-12-12 | — | — | US | disclosed |
| US-5948451-A | Method of modifying the balance of omega unsaturated fatty acids using a dioxabicyclo octane derivative | SUNTORY LIMITED (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0782827-A1 | FOOD COMPOSITION CONTAINING BALANCING AGENT FOR $g(v)-6 AND $g(v)-3 UNSATURATED FATTY ACIDS | SUNTORY LIMITED (JP) | 1997-07-09 | — | — | EP | disclosed |
| US-5034414-A | Nutrients in emulsions for transfusions containing unsaturated acids and esters | TERUMO KABUSHIKI KAISHA (JP) | 1991-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | ADORA3 2989/4885NR1I2 2913/4885PTGS2 1263/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | ADORA3 293/4885NR1I2 1746/4885PTGS2 1237/4885 |
| US-11690820-B2 | Methods of treating mixed dyslipidemia | LIPA, LIPC, PNLIP | ADORA3 1704/4885NR1I2 1184/4885PTGS2 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.